ArticleAnnals of the rheumatic diseases2010

Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?

A Finckh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.